Corcept Therapeutics Incorporated - CORT Total Company Value-to-Revenue Ratio

Public company logo of Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics (CORT) is scaling its portfolio of cortisol modulators to combat oncology and metabolic disorders. The firm's EV/Sales multiple valuation demonstrates this growth, while the 7004.52 metric indicates the status of its current value. Success is based on its monopoly in Cushing's syndrome therapy and Korlym, as well as scientific partnerships with leading endocrinology centers to develop complex treatment methods.

CORT Corcept Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

CORT (corcept.com): analytical breakdowns and indicator data

Initial company analysis:Corcept Therapeutics CORT
Manufactured product of Corcept Therapeutics

This indicator determines the enterprise value of Corcept Therapeutics (CORT) by accounting for net debt and comparing it to sales volume to eliminate the impact of financial leverage. By analyzing the EV/Revenue ratio on the GURU.Markets platform, an investor assesses the monetization efficiency of drugs for the therapy of Cushing's syndrome, where a high valuation is justified by patent exclusivity and the growth potential of the metabolic correction market.

Competitor analysis for Corcept Therapeutics

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|RYTM - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Akero Corp|Metsera Therapeutics (MTSR) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio moonlaketx.com (MLTX)|Company Value to Revenue Crinetics Pharmaceuticals CRNX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)